Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma
Jessica Okosun,Rachel L Wolfson,Jun Wang,Shamzah Araf,Lucy Wilkins,Brian M Castellano,Leire Escudero-Ibarz,Ahad Fahad Al Seraihi,Julia Richter,Stephan H Bernhart,Alejo Efeyan,Sameena Iqbal,Janet Matthews,Andrew Clear,José Afonso Guerra-Assunção,Csaba Bödör,Hilmar Quentmeier,Christopher Mansbridge,Peter Johnson,Andrew Davies,Jonathan C Strefford,Graham Packham,Sharon Barrans,Andrew Jack,Ming-Qing Du,Maria Calaminici,T Andrew Lister,Rebecca Auer,Silvia Montoto,John G Gribben,Reiner Siebert,Claude Chelala,Roberto Zoncu,David M Sabatini,Jude Fitzgibbon
DOI: https://doi.org/10.1038/ng.3473
Abstract:Follicular lymphoma is an incurable B cell malignancy characterized by the t(14;18) translocation and mutations affecting the epigenome. Although frequent gene mutations in key signaling pathways, including JAK-STAT, NOTCH and NF-κB, have also been defined, the spectrum of these mutations typically overlaps with that in the closely related diffuse large B cell lymphoma (DLBCL). Using a combination of discovery exome and extended targeted sequencing, we identified recurrent somatic mutations in RRAGC uniquely enriched in patients with follicular lymphoma (17%). More than half of the mutations preferentially co-occurred with mutations in ATP6V1B2 and ATP6AP1, which encode components of the vacuolar H(+)-ATP ATPase (V-ATPase) known to be necessary for amino acid-induced activation of mTORC1. The RagC variants increased raptor binding while rendering mTORC1 signaling resistant to amino acid deprivation. The activating nature of the RRAGC mutations, their existence in the dominant clone and their stability during disease progression support their potential as an excellent candidate for therapeutic targeting.